E-LIB Suche - Ergebnisse für: Manzke, Oliver

1

IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + Lenalido..:

Sehn, Laurie H. ; Scholz, Christian W. ; Luminari, Stefano...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S402 , 2021

Link: https://doi.org/10.1016/..

2

Poster: IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + ..:

Sehn, Laurie H. ; Scholz, Christian W. ; Luminari, Stefano...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S246 , 2021

Link: https://doi.org/10.1016/..

3

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in..:

Nowakowski, Grzegorz S. ; Willenbacher, Wolfgang ; Greil, Richard...
International Journal of Hematology. 115 (2021) 2 - p. 222-232 , 2021

Link: https://doi.org/10.1007/..

4

Identification and characterization of embryonic stem cell‐..:

Kolossov, Eugen ; Lu, Zhongju ; Drobinskaya, Irina...
The FASEB Journal. 19 (2005) 6 - p. 1-25 , 2005

Link: https://doi.org/10.1096/..

5

Modulation of MUC1 and blood group antigen expression in ga..:

Grohmann, Georg P.M ; Schirmacher, Peter ; Manzke, Oliver...
Cytokine. 23 (2003) 3 - p. 86-93 , 2003

Link: https://doi.org/10.1016/..

6

Locoregional treatment of low-grade B-cell lymphoma with CD..:

Manzke, Oliver ; Tesch, Hans ; Borchmann, Peter...
International Journal of Cancer. 91 (2001) 4 - p. 508-515 , 2001

Link: https://doi.org/10.1002/..

7

Immunotherapeutic strategies in neuroblastoma: Antitumoral ..:

Manzke, Oliver ; Russello, Orsolina ; Leenen, Christiane...
Medical and Pediatric Oncology. 36 (2001) 1 - p. 185-189 , 2001

Link: https://doi.org/10.1002/..

8

Locoregional treatment of low-grade B-cell lymphoma with CD..:

Manzke, Oliver ; Tesch, Hans ; Lorenzen, Johann..
International Journal of Cancer. 91 (2001) 4 - p. 516-522 , 2001

Link: https://doi.org/10.1002/..

9

Vaccination of multiple myeloma patients with idiotype‐puls..:

Titzer, Sandra ; Christensen, Olaf ; Manzke, Oliver...
British Journal of Haematology. 108 (2000) 4 - p. 805-816 , 2000

Link: https://doi.org/10.1046/..

10

CD3� anti-nitrophenyl bispecific diabodies: Universal immun..:

Manzke, Oliver ; Fitzgerald, Kevin J. ; Holliger, Philipp...
International Journal of Cancer. 82 (1999) 5 - p. 700-708 , 1999

Link: https://doi.org/10.1002/..

11

CD3xCD19 bispecific antibodies and CD28 bivalent antibodies..:

Manzke, Oliver ; Berthold, Frank ; Huebel, Kai...
International Journal of Cancer. 80 (1999) 5 - p. 715-722 , 1999

Link: https://doi.org/10.1002/..

12

Bispezifische Antikörper — Werkzeuge zur T-Zell Rekrutierun:

, In: Tumorerkrankungen,

Bohlen, Heribert ; Manzke, Oliver ; Tesch, Hans - p. 186-198 , 1998

Link: https://doi.org/10.1007/..

13

Single-step purification of bispecific monoclonal antibodie..:

Manzke, Oliver ; Tesch, Hans ; Diehl, Volker.
Journal of Immunological Methods. 208 (1997) 1 - p. 65-73 , 1997

Link: https://doi.org/10.1016/..

14

CD3×CD19 bispecific antibodies and CD28 costimulation for l..:

Manzke, Oliver ; Titzer, Sandra ; Tesch, Hans..
Cancer Immunology, Immunotherapy. 45 (1997) 3-4 - p. 198-202 , 1997

Link: https://doi.org/10.1007/..

15

A Phase 2/3 Multicenter, Randomized Study Comparing the Eff..:

Czuczman, Myron S ; Davies, Andrew ; Linton, Kim...
Czuczman , M S , Davies , A , Linton , K , Wagner-Johnston , N , Gascoyne , R D , Eberhard , D A , Salles , G , Witzig , T E , Zinzani , P L , Wright , G W , Staudt , L M , Repici , J , Song , D , Manzke , O & Lewis , I D 2015 , A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL. 628, 2014 . in A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL . ASH Education Book , no. 21628 , vol. 124 , American Society of Hematology Annual Conference , New Orleans , 1/01/24 .. , 2015

Link: https://research.manches..